加载中
Chemomab Therapeutics Ltd. operates as a clinical-stage biotechnology firm, dedicated to identifying and advancing novel treatments for inflammatory and fibrotic conditions. Its leading experimental drug candidate, CM-101, is a humanized monoclonal antibody specifically engineered to impede the core function of soluble chemokine CCL24. This potential therapy is currently under investigation for its efficacy in managing primary sclerosing cholangitis (PSC) and systemic sclerosis (SSc). Established in 2011, the company, formerly known as Anchiano Therapeutics Ltd., adopted its current name, Chemomab Therapeutics Ltd., in March 2021 and is headquartered in Tel Aviv, Israel.
前收盘价
US$1.38
−US$0.01 · -0.72%
盘中时间采用ET。市场数据可能有所延迟。
Chemomab Therapeutics Ltd. operates as a clinical-stage biotechnology firm, dedicated to identifying and advancing novel treatments for inflammatory and fibrotic conditions. Its leading experimental drug candidate, CM-101, is a humanized monoclonal antibody specifically engineered to impede the core function of soluble chemokine CCL24. This potential therapy is currently under investigation for its efficacy in managing primary sclerosing cholangitis (PSC) and systemic sclerosis (SSc). Established in 2011, the company, formerly known as Anchiano Therapeutics Ltd., adopted its current name, Chemomab Therapeutics Ltd., in March 2021 and is headquartered in Tel Aviv, Israel.
日内区间
当前US$1.38
52周区间
当前US$1.38
盘中时间采用ET。市场数据可能有所延迟。
Chemomab Therapeutics Ltd. operates as a clinical-stage biotechnology firm, dedicated to identifying and advancing novel treatments for inflammatory and fibrotic conditions. Its leading experimental drug candidate, CM-101, is a humanized monoclonal antibody specifically engineered to impede the core function of soluble chemokine CCL24. This potential therapy is currently under investigation for its efficacy in managing primary sclerosing cholangitis (PSC) and systemic sclerosis (SSc). Established in 2011, the company, formerly known as Anchiano Therapeutics Ltd., adopted its current name, Chemomab Therapeutics Ltd., in March 2021 and is headquartered in Tel Aviv, Israel.
日内区间
当前US$1.38
52周区间
当前US$1.38
营业利润
净利润
| 项目（USD） | 2025财年 | 2024财年 | 2023财年 | 2022财年 | 2021财年 |
|---|---|---|---|---|---|
| 销货成本 | — | — | 6.68万 USD | 5.78万 USD | 3.4万 USD |
| 毛利 | — | — | −6.68万 USD | −5.78万 USD | −3.4万 USD |
| 研究与开发 | 583.3万 USD | 1132.7万 USD | 1838.1万 USD | 1697.7万 USD | 630.44万 USD |
| 销售、一般及管理费用 | 373.4万 USD | 341.2万 USD | 707.8万 USD | 1155.6万 USD | 603.72万 USD |
| 营业费用 | 956.7万 USD | 1473.9万 USD | 2545.9万 USD | 2853.3万 USD | 1234.15万 USD |
| 利息收入 | 57.2万 USD | 79.4万 USD | 123.5万 USD | 35.16万 USD | — |
| 利息支出 | — | — | — | 35.3万 USD | 11.11万 USD |
| 折旧和摊销 | 7万 USD | 5.3万 USD | 6.7万 USD | 5.78万 USD | 3.4万 USD |
| 营业利润 | −956.7万 USD | −1473.9万 USD | −2545.9万 USD | −2853.3万 USD | −1237.56万 USD |
| 净利润 | −899.5万 USD | −1394.5万 USD | −2422.1万 USD | −2764.6万 USD | −1248.66万 USD |
公司数据更新于 2026年10月11日。
近期已公布业绩
AI 生成内容及延迟市场数据仅供信息与教育用途，不构成投资建议。
